Mutations ACE2 - Uniprot
Par Naoum Salamé
—
Dernière modification
05/03/2024 09:44
UNIPROT - ACE2 - Mutagenesis
| Mutagenesisi | 24 – 26 | QAK → KAE: Slightly inhibits interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 31 | K → D: Abolishes interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 37 | E → A: No effect on interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 38 | D → A: No effect on interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 41 | Y → A: Strongly inhibits interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 68 | K → D: Slightly inhibits interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 82 – 84 | MYP → NFS: Inhibits interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 110 | E → P: No effect on interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 135 – 136 | PD → SM: No effect on interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 160 | E → R: No effect on interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 169 | R → Q: About 95% loss of angiotensin I cleavage. |
| Mutagenesisi | 192 | R → D: No effect on interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 219 | R → D: No effect on interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 239 | H → Q: No effect on interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 271 | W → Q: About 95% loss of angiotensin I cleavage. |
| Mutagenesisi | 273 | R → Q: Complete loss of enzyme activity. Does not affect amino acid transport activity of SLC6A19. |
| Mutagenesisi | 309 | K → D: No effect on interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 312 | E → A: No effect on interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 324 | T → A: No effect on interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 338 – 340 | NVQ → DDR: No effect on interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 345 | H → A: Complete loss of enzyme activity. |
| Mutagenesisi | 350 | D → A: No effect on interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 353 | K → H, A or D: Abolishes interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 355 | D → A: Strongly inhibits interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 357 | R → A: Strongly inhibits interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 359 | L → K or A: No effect on interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 383 | M → A: Slightly inhibits interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 389 | P → A: Slightly inhibits interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 393 | R → A: Slightly inhibits interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 425 – 427 | SPD → PSN: Slightly inhibits interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 465 – 467 | KGE → QDK: No effect on interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 481 | K → Q: About 80% loss of angiotensin I cleavage. |
| Mutagenesisi | 505 | H → A: Complete loss of enzyme activity. |
| Mutagenesisi | 514 | R → Q: About 50% loss of angiotensin I cleavage but two-fold greater activity with angiotensin II. |
| Mutagenesisi | 559 | R → S: Slightly inhibits interaction with SARS-CoV spike glycoprotein. |
| Mutagenesisi | 603 | F → T: No effect on interaction with SARS-CoV spike glycoprotein. |